Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art

<b>Background</b>: Aggressive and metastatic PitNETs are challenging conditions. Immune checkpoint inhibitors (ICIs) are currently considered in cases resistant to temozolomide (TMZ). However, clinical experience is essentially limited to case reports, with variable outcomes. <b>Ma...

Full description

Bibliographic Details
Main Authors: Tiziana Feola, Francesca Carbonara, Monica Verrico, Rosa Maria Di Crescenzo, Francesca Gianno, Claudio Colonnese, Antonietta Arcella, Dario de Alcubierre, Silverio Tomao, Vincenzo Esposito, Felice Giangaspero, Giuseppe Minniti, Marie-Lise Jaffrain-Rea
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
aggressive pituitary tumors
pituitary carcinoma
pituitary neuroendocrine tumors (PitNETs)
temozolomide
radiotherapy
PDL1
Online Access:https://www.mdpi.com/2072-6694/14/17/4093

Internet

https://www.mdpi.com/2072-6694/14/17/4093

Similar Items